Corixa Acquisition Of Coulter Gives Company Bexxar, Pending At FDA
Executive Summary
Corixa's acquisition of Coulter will give the company its most advanced late-stage clinical product, the non-Hodgkin's lymphoma therapy Bexxar.
You may also be interested in...
Coulter Bexxar
New NDA filing for the iodine I 131 tositumomab product is no longer expected by mid-October, CEO Michael Bigham told analysts Sept. 28. The Aug. 27 "refuse-to-file" letter from FDA required Coulter to reformat selected data sets, reorganize certain analyses and provide archival images. Bigham said a meeting the company requested with FDA will not take place until mid-October, delaying the resubmission. Co-marketing partner SmithKline Beecham has indicated that it is helping Coulter with the submission (1"The Pink Sheet" Sept. 27, p. 22)
Corixa Garners Manufacturing Facility For Pvac Through Merger With Ribi
Corixa may produce its Pvac immunotherapeutic at Ribi's Hamiliton, Mont. facility following the companies' merger.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011